OneSource Specialty Pharma shares fall as Q4 profit plunges 95%, margin halves

Shares of OneSource Specialty Pharma Ltd. dropped more than 5% on Wednesday, May 13, after the company reported a sharp decline in quarterly profit and operating performance for the March quarter.

Consolidated net profit for Q4FY26 fell to ₹4.6 crore from ₹98.5 crore in the year-ago period. While revenue rose marginally to ₹428.2 crore from ₹426 crore a year ago, Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) declined 50% year-on-year to ₹92 crore from ₹182 crore.

EBITDA margin contracted sharply to 21.5% from 42.7% in the corresponding quarter last year. The company reported a loss before tax of ₹3 crore for the quarter, compared to a profit before tax of ₹84 crore in the year-ago period.

Also read: TVS Motor Q4 Results: Profit rises 33%, EBITDA tops estimates

For FY26, revenue from operations stood at ₹1,421.6 crore, compared to ₹1,448.5 crore in FY25. The company reported a consolidated net loss of ₹73.8 crore for FY26 against a profit of ₹179.7 crore in the previous year. Finance costs for the quarter also rose to ₹22.4 crore from ₹5.4 crore a year ago.

During the quarter, OneSource received regulatory approval for its proposed acquisition of the oral biologics facility of Steriscience Specialties Pvt. Ltd. from the Competition Commission of India. The board is evaluating further steps for proceeding with the acquisition.

Shares of the company fell 5.4% following the result announcement, hitting an intraday low of ₹1,731. As of 1.36 pm on Wednesday, the stock was trading 4.28% down at ₹1,751.80. It has erased all the gains it made over the last six months.